

RECAP IQ DEAL BUILDER

HOW DO I CONDUCT DUE DILIGENCE ON A POTENTIAL PARTNER?

USE CASE

I'm looking for all of the alliances associated with Amgen.

HOW TO CONSTRUCT

Go to Index > Alliances and Search for "Amgen". A list of all the Amgen alliances available in the database is provided.

Alliance Index

Use the Alliance Index to look up all the alliances for a biotech or pharmaceutical company. Type the company name and click 'Find', or use the letter selection to browse the company names.

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Select a letter range to display the companies starting with those letters.

-Amgen-

- Amgen
- Amgen Clinical Partners
- Amgen Foundation
- Amgen, Celldex Therapeutics

Alliances: Amgen

Page 1 of 17 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next

Parties	Date	Type	Size	Upfront	Total Milestone	Royalty	Subject
Onyx Pharmaceuticals / Amgen	06/2013	Acq	\$8,760.0	\$8,760.0			Unsolicited offer to acquire Onyx Pharmaceuticals for \$8.76B @ \$120/sh in cash
Cytokinetics / Amgen	06/2013	Col, L	\$75.0	\$15.0	\$50.0		Expansion of 12/2006 collaboration to develop cardiac myosin activator program to include Japanese rights (now has worldwide rights)
Amgen / Zhejiang Beta Pharma	05/2013	JV					51/49 JV (Amgen-Beta Pharmaceuticals Co.), to commercialize Vectibix (panitumumab) for metastatic colorectal cancer (mCRC) in China
Transgenomic / Amgen	05/2013	Col, L					Surveyor-Wave technology to develop a CE-IVD test to screen patients with metastatic colorectal cancer (mCRC) for RAS mutations
Amgen / Astellas Pharma	05/2013	JV					51/49 JV (Amgen Astellas BioPharma KK) to develop and commercialize five Amgen drugs, including Phase III-stage romosozumab (AMG 785) for osteoporosis in Japan
Tetragenetics / Amgen	04/2013	Col, L					TetraExpress technology for tetrahymena-based expression of an Amgen antigen target for antibody development
BIND Biosciences / Amgen	01/2013	Col, L	\$180.5	\$-1.0	\$-1.0		Accurin nanoparticle delivery technology with Amgen kinase inhibitor for solid tumors worldwide



RESULTS

- Click on a particular alliance to get the detail of the alliance.
- Once in a particular alliance record, click on the “Amgen” company name to link to the organization’s profile providing a summary of:
 - Alliances
 - Clinical Indications
 - Patents
 - Internal Contacts
 - SEC Filings

Company: Amgen

Category: Biotech TickDisp: NASDAQ - AMGN
 Website: www.Amgen.com

Alliances Contracts Clinical Indications Patents Filings Contacts

Page 1 of 17 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next

Parties	Date	Type	Size	Upfront	Total Milestone	Royalty	Subject
Onyx Pharmaceuticals / Amgen	06/2013	Acq	\$8,760.0	\$8,760.0			Unsolicited offer to acquire Onyx Pharmaceuticals for \$8.76B @ \$120/sh in cash
Cytokinetics / Amgen	06/2013	CoL L	\$75.0	\$15.0	\$50.0		Expansion of 12/2006 collaboration to develop cardiac myosin activator program to include Japanese rights (now has worldwide rights)
Amgen / Zhejiang Beta Pharma	05/2013	JV					51/49 JV (Amgen-Beta Pharmaceuticals Co.), to commercialize Vectibix (panitumumab) for metastatic colorectal cancer (mCRC) in China
Transgenomic / Amgen	05/2013	CoL L					Surveyor-Wave technology to develop a CE-IVD test to screen patients with metastatic colorectal cancer (mCRC) for RAS mutations
Amgen / Astellas Pharma	05/2013	JV					51/49 JV (Amgen Astellas BioPharma KK) to develop and commercialize five Amgen drugs, including Phase III-stage <i>comazine</i> (AMC 795) for